Ovarian cancer today and tomorrow: A global assessment by world region and Human Development Index using GLOBOCAN 2020

Abstract

Ovarian cancer remains to have relatively poor prognosis particularly in low-resourced settings. It is therefore important to continually examine the burden of ovarian cancer to identify areas of disparities. Our study aims to provide an overview of the global burden of ovarian cancer using the GLOBOCAN 2020 estimates by country, world region, and Human Development Index (HDI) levels, as well as the predicted future burden by the year 2040 by HDI. Age-standardized incidence and mortality rates for ovarian cancer in 185 countries were calculated by country, world region, and for the four-tier HDI. The number of new cases and deaths were projected for the year 2040 based on demographic projections by HDI category. Approximately 314 000 new ovarian cancer cases and 207 000 deaths occurred in 2020. There were marked geographic variations in incidence rates, with the highest rates observed in European countries with very high HDI and low rates were found in African countries within the lowest HDI group. Comparable mortality rates were observed across the four-tier HDI. Relative to 2020 estimates, our projection for 2040 indicates approximately 96% and 100% increase in new ovarian cancer cases and deaths, respectively, among low HDI countries compared to 19% and 28% in very high HDI countries. Our study highlights the disproportionate current and future burden of ovarian cancer in countries with lower HDI levels, calling for global action to reduce the burden and inequality of ovarian cancer in access to quality cancer care and treatment.

HBOC syndrome with an uncharacterized variant in the BRCA1 gene in a patient diagnosed with endometrial cancer after surgery for bilateral breast cancer: A case report

“…There were approximately 2.3 million new breast cancer cases and 685,000 breast cancer deaths worldwide in 2020 ( 5 ). Approximately 314,000 new ovarian cancer cases and 207,000 deaths occurred globally in 2020 ( 6 ). Among patients with breast cancers between 35 and 64 years old in the USA, 2.4 and 2.3% carried deleterious mutations in BRCA1 and BRCA2 , respectively ( 2 ).…”

The global, regional and national epidemiology, incidence, mortality, and burden of ovarian cancer

“…33 Part of the increase in ovarian cancer-related mortality can be justified by inequalities in disease-related care and treatment protocols as well as the standards of these protocols, although genetic susceptibility, comorbidity, and increased risk factors also play a role in this regard. 34,35 The use of modern diagnosis and treatment methods for ovarian cancer can reduce its mortality rate, although not enough data are available to compare different parts of the world in this regard. 35 However, it seems that this factor can explain part of the ovarian cancer mortality rate.…”

Trends in the incidence of ovarian cancer in sub‐Saharan Africa

“…Worldwide, ovarian cancer (OC) was the eighth most commonly diagnosed cancer among women in 2020, with an estimated 314 000 new cases, and the eighth most common cause of cancer death, with 207 000 deaths in the same year 1,2 . The incidence and mortality rates of OC vary between different regions, with the highest age standardised incidence rates observed in Europe and North America 2‐5 …”

“…Worldwide, ovarian cancer (OC) was the eighth most commonly diagnosed cancer among women in 2020, with an estimated 314 000 new cases, and the eighth most common cause of cancer death, with 207 000 deaths in the same year. 1,2 The incidence and mortality rates of OC vary between different regions, with the highest age standardised incidence rates observed in Europe and North America. [2][3][4][5] Almost 18 000 cases and 13 000 deaths from ovarian cancer were estimated to have occurred in the sub-Saharan African (SSA) region in 2020, constituting 2.2% of all cancer cases (both sexes), with the disease ranking the fourth most frequent neoplasm in women.…”